Medtronic plc announced it received U.S. Food and Drug Administration (FDA) approval for the Onyx Frontier(TM) drug-eluting stent (DES). As the latest evolution in the Resolute DES family, Onyx Frontier DES leverages the same best-in-class stent platform as Resolute Onyx(TM) DES, with an enhanced delivery system designed to improve deliverability and increase acute performance in even the most challenging of cases.